183 related articles for article (PubMed ID: 35309122)
1. A Gene Panel for Early Identification of Future Responders to Immune Checkpoint Blockade.
Panda A; Betigeri A; Ganesan S
Front Genet; 2022; 13():706468. PubMed ID: 35309122
[TBL] [Abstract][Full Text] [Related]
2. Systematic Assessment of Transcriptomic Biomarkers for Immune Checkpoint Blockade Response in Cancer Immunotherapy.
Sun S; Xu L; Zhang X; Pang L; Long Z; Deng C; Zhu J; Zhou S; Wan L; Pang B; Xiao Y
Cancers (Basel); 2021 Apr; 13(7):. PubMed ID: 33915876
[TBL] [Abstract][Full Text] [Related]
3. The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma.
Mahoney KM; Freeman GJ; McDermott DF
Clin Ther; 2015 Apr; 37(4):764-82. PubMed ID: 25823918
[TBL] [Abstract][Full Text] [Related]
4. Biomarkers of Immune Checkpoint Blockade Response in Triple-Negative Breast Cancer.
Isaacs J; Anders C; McArthur H; Force J
Curr Treat Options Oncol; 2021 Mar; 22(5):38. PubMed ID: 33743085
[TBL] [Abstract][Full Text] [Related]
5. Robust prediction of response to immune checkpoint blockade therapy in metastatic melanoma.
Auslander N; Zhang G; Lee JS; Frederick DT; Miao B; Moll T; Tian T; Wei Z; Madan S; Sullivan RJ; Boland G; Flaherty K; Herlyn M; Ruppin E
Nat Med; 2018 Oct; 24(10):1545-1549. PubMed ID: 30127394
[TBL] [Abstract][Full Text] [Related]
6. PD-L1 Tumor Expression as a Predictive Biomarker of Immune Checkpoint Inhibitors' Response and Survival in Advanced Melanoma Patients in Brazil.
Sorroche BP; Teixeira RJ; Pereira CAD; Santana IVV; Vujanovic L; Vazquez VL; Arantes LMRB
Diagnostics (Basel); 2023 Mar; 13(6):. PubMed ID: 36980349
[TBL] [Abstract][Full Text] [Related]
7. Insignificant effects of loss of heterozygosity in HLA in the efficacy of immune checkpoint blockade treatment.
Yang Y; Kim E; Kim S
Genes Genomics; 2022 Apr; 44(4):509-515. PubMed ID: 35107815
[TBL] [Abstract][Full Text] [Related]
8. Mechanisms underlying response and resistance to immune checkpoint blockade in cancer immunotherapy.
Lee J; Kim EH
Front Oncol; 2023; 13():1233376. PubMed ID: 37614504
[TBL] [Abstract][Full Text] [Related]
9. Local and Targeted Delivery of Immune Checkpoint Blockade Therapeutics.
Han X; Li H; Zhou D; Chen Z; Gu Z
Acc Chem Res; 2020 Nov; 53(11):2521-2533. PubMed ID: 33073988
[TBL] [Abstract][Full Text] [Related]
10. The foundations of immune checkpoint blockade and the ipilimumab approval decennial.
Korman AJ; Garrett-Thomson SC; Lonberg N
Nat Rev Drug Discov; 2022 Jul; 21(7):509-528. PubMed ID: 34937915
[TBL] [Abstract][Full Text] [Related]
11. Monocyte-derived APCs are central to the response of PD1 checkpoint blockade and provide a therapeutic target for combination therapy.
Schetters STT; Rodriguez E; Kruijssen LJW; Crommentuijn MHW; Boon L; Van den Bossche J; Den Haan JMM; Van Kooyk Y
J Immunother Cancer; 2020 Jul; 8(2):. PubMed ID: 32690667
[TBL] [Abstract][Full Text] [Related]
12. Photothermal therapies to improve immune checkpoint blockade for cancer.
Balakrishnan PB; Sweeney EE; Ramanujam AS; Fernandes R
Int J Hyperthermia; 2020 Dec; 37(3):34-49. PubMed ID: 33426992
[TBL] [Abstract][Full Text] [Related]
13. Tumor CD155 Expression Is Associated with Resistance to Anti-PD1 Immunotherapy in Metastatic Melanoma.
Lepletier A; Madore J; O'Donnell JS; Johnston RL; Li XY; McDonald E; Ahern E; Kuchel A; Eastgate M; Pearson SA; Mallardo D; Ascierto PA; Massi D; Merelli B; Mandala M; Wilmott JS; Menzies AM; Leduc C; Stagg J; Routy B; Long GV; Scolyer RA; Bald T; Waddell N; Dougall WC; Teng MWL; Smyth MJ
Clin Cancer Res; 2020 Jul; 26(14):3671-3681. PubMed ID: 32345648
[TBL] [Abstract][Full Text] [Related]
14. Opposing Functions of Interferon Coordinate Adaptive and Innate Immune Responses to Cancer Immune Checkpoint Blockade.
Benci JL; Johnson LR; Choa R; Xu Y; Qiu J; Zhou Z; Xu B; Ye D; Nathanson KL; June CH; Wherry EJ; Zhang NR; Ishwaran H; Hellmann MD; Wolchok JD; Kambayashi T; Minn AJ
Cell; 2019 Aug; 178(4):933-948.e14. PubMed ID: 31398344
[TBL] [Abstract][Full Text] [Related]
15. A whole-blood RNA transcript-based gene signature is associated with the development of CTLA-4 blockade-related diarrhea in patients with advanced melanoma treated with the checkpoint inhibitor tremelimumab.
Friedlander P; Wood K; Wassmann K; Christenfeld AM; Bhardwaj N; Oh WK
J Immunother Cancer; 2018 Sep; 6(1):90. PubMed ID: 30227886
[TBL] [Abstract][Full Text] [Related]
16. Pretreatment Innate Cell Populations and CD4 T Cells in Blood Are Associated With Response to Immune Checkpoint Blockade in Melanoma Patients.
Pirozyan MR; McGuire HM; Emran AA; Tseng HY; Tiffen JC; Lee JH; Carlino MS; Menzies AM; Long GV; Scolyer RA; Fazekas de St Groth B; Hersey P
Front Immunol; 2020; 11():372. PubMed ID: 32210968
[TBL] [Abstract][Full Text] [Related]
17. From Co-Stimulation to Co-Inhibition: A Continuum of Immunotherapy Care Toward Long-Term Survival in Melanoma.
Simonetti E; Cutarella S; Valente M; Sani T; Ravara M; Maio M; Di Giacomo AM
Onco Targets Ther; 2023; 16():227-232. PubMed ID: 37041860
[TBL] [Abstract][Full Text] [Related]
18. Early memory differentiation and cell death resistance in T cells predicts melanoma response to sequential anti-CTLA4 and anti-PD1 immunotherapy.
Vanmeerbeek I; Borras DM; Sprooten J; Bechter O; Tejpar S; Garg AD
Genes Immun; 2021 Jun; 22(2):108-119. PubMed ID: 34079092
[TBL] [Abstract][Full Text] [Related]
19. Tumor Interferon Signaling Regulates a Multigenic Resistance Program to Immune Checkpoint Blockade.
Benci JL; Xu B; Qiu Y; Wu TJ; Dada H; Twyman-Saint Victor C; Cucolo L; Lee DSM; Pauken KE; Huang AC; Gangadhar TC; Amaravadi RK; Schuchter LM; Feldman MD; Ishwaran H; Vonderheide RH; Maity A; Wherry EJ; Minn AJ
Cell; 2016 Dec; 167(6):1540-1554.e12. PubMed ID: 27912061
[TBL] [Abstract][Full Text] [Related]
20. Mechanisms of immunogenic cell death and immune checkpoint blockade therapy.
Lin RA; Lin JK; Lin SY
Kaohsiung J Med Sci; 2021 Jun; 37(6):448-458. PubMed ID: 33636043
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]